Meta-Flux Limited
Meta-Flux provides an AI-driven drug-discovery platform that rapidly identifies novel disease targets, elucidates mechanisms of action, predicts toxicity, and supports clinical-trial design with predictive analytics. The platform delivers high-confidence leads and actionable insights—reducing costly trial-and-error and empowering data-driven decisions from pilot studies to full clinical programmes. Tailored to each startups' needs, Meta-Flux combines scientific expertise with scalable cloud-GPU architecture to uncover critical pathways and accelerate success across the drug-development pipeline. Recent impact includes helping Celtic Bio refine its respiratory pipeline by pinpointing first-in-class targets and streamlining pre-clinical studies. Through outcome-linked pricing, Meta-Flux aligns incentives with partners to derisk innovation and speed transformative therapies to patients.
Services from this partner are open to EIC beneficiaries at the stages listed on each service page. Where EIC ACCESS+ applies, co-funding covers 50% of the full amount.
